1. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. Issue 8 (August 2022) Authors: Malaba, Thokozile R; Nakatudde, Irene; Kintu, Kenneth; Colbers, Angela; Chen, Tao; Reynolds, Helen; Read, Lucy; Read, Jim; Stemmet, Lee-Ann; Mrubata, Megan; Byrne, Kelly; Seden, Kay; Twimukye, Adelline; Theunissen, Helene; Hodel, Eva Maria; Chiong, Justin; Hu, Nai-Chung; Burger, David; Wang, Duol... Journal: Lancet Issue: Volume 9:Issue 8(2022) Page Start: e534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. (17th February 2015) Authors: Mora-Peris, Borja; Else, Laura; Goldmeier, David; Mears, Alison; Weston, Rosy; Cooke, Graham; Khoo, Saye; Back, David; Winston, Alan Journal: Journal of antimicrobial chemotherapy Issue: Volume 70:Number 6(2015:Jun.) Page Start: 1812 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection. Issue 3 (June 2016) Authors: Wang, Xinzhu; Penchala, Sujan Dilly; Amara, Alieu; Else, Laura; McClure, Myra; Boffito, Marta Journal: Therapeutic drug monitoring Issue: Volume 38:Issue 3(2016:Jun.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2. Issue 3 (13th November 2021) Authors: Walker, Lauren E.; FitzGerald, Richard; Saunders, Geoffrey; Lyon, Rebecca; Fisher, Michael; Martin, Karen; Eberhart, Izabela; Woods, Christie; Ewings, Sean; Hale, Colin; Rajoli, Rajith K. R.; Else, Laura; Dilly‐Penchala, Sujan; Amara, Alieu; Lalloo, David G.; Jacobs, Michael; Pertinez, Henry; Hat... Journal: Clinical pharmacology & therapeutics Issue: Volume 111:Issue 3(2022) Page Start: 585 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. (20th January 2015) Authors: Di Yacovo, Maria S.; Moltó, José; Ferrer, Elena; Curran, Adrian; Else, Laura; Gisslén, Magnus; Clotet, Bonaventura; Tiraboschi, Juan M.; Niubò, Jordi; Vila, Antonia; Zetterberg, H.; Back, David; Podzamczer, Daniel Journal: Journal of antimicrobial chemotherapy Issue: Volume 70:Number 5(2015:May) Page Start: 1513 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. (1st November 2016) Authors: Fox, Julie; Tiraboschi, Juan M.; Herrera, Carolina; Else, Laura; Egan, Deirdre; Dickinson, Laura; Jackson, Akil; Olejniczak, Natalia; Back, David; Khoo, Saye; Shattock, Robin; Boffito, Marta Journal: Journal of acquired immune deficiency syndromes Issue: Volume 73:Number 3(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Cerebrospinal fluid exposure of cenicriviroc in HIV‐positive individuals with cognitive impairment. Issue 5 (4th March 2019) Authors: Alagaratnam, Jasmini; Dilly‐Penchala, Sujan; Challenger, Elizabeth; Else, Laura; Legg, Ken; Petersen, Claire; Jones, Brynmor; Kulasegaram, Ranjababu; Seyedkazemi, Star; Lefebvre, Eric; Khoo, Saye; Winston, Alan Journal: British journal of clinical pharmacology Issue: Volume 85:Issue 5(2019) Page Start: 1039 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. (29th March 2021) Authors: Harvala, Heli; Reynolds, Claire; Ijaz, Samreen; Maddox, Vicki; Penchala, Sujan Dilly; Amara, Alieu; Else, Laura; Brailsford, Susan; Khoo, Saye Journal: Sexually transmitted infections Issue: Volume 98:issue 2(2022) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. (3rd February 2020) Authors: Elliot, Emilie R; Neary, Megan; Else, Laura; Khoo, Saye; Moyle, Graeme; Carr, Daniel F; Wang, Xinzhu; Mcclure, Myra; Boffito, Marta; Owen, Andrew Journal: Journal of antimicrobial chemotherapy Issue: Volume 75:Number 5(2020) Page Start: 1259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Genital Secretion HIV RNA Shedding in HIV-Positive Patients on Ritonavir-Boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-Sectional Sub-Study from the PIVOT Trial. Issue 1 (January 2020) Authors: Arenas-Pinto, Alejandro; Stöhr, Wolfgang; Khoo, Saye; Clarke, Amanda; Beeching, Nicholas; Warwick, Zoe; Lee, Vincent; Else, Laura; Wiggins, Rebecca; Ferns, Bridget; Nastouli, Eleni; Dunn, David; Lacey, Charles J; Paton, Nicholas I Journal: Antiviral therapy Issue: Volume 25:Issue 1(2020) Page Start: 55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗